Washington is usually quiet in August, as lawmakers go home and government officials take vacations. This year, teams of health policy staffers are working overtime to finalize regulations, fine-tune IT systems and work with states and insurers to get exchanges ready by October 1.
These efforts were side-tracked last month by rebukes from Republicans about the one-year delay in enforcing the employer mandate. Two House committees put Treasury Department and Health and Human Services (HHS) officials on the hot seat at hearings on the operational and financial impacts of postponing.
Administration leaders explained that the delay is necessary to provide companies time to implement new rules on providing information on workforce size, compensation and coverage. Such data is needed for the IRS and exchange operators to calculate coverage affordability and individual eligibility for subsidies.
The delay could eliminate some $10 billion in previously expected revenue coming from fines on employers failing to provide coverage. More workers may look to exchanges for coverage and subsidies, further raising program costs.
The mandate delay also encouraged House leaders to schedule votes on bills to postpone the individual mandate and to codify delay in enforcing the employer mandate. The measures had support from only a few Democrats and have little chance of enactment, but the votes give Republicans ammunition to use against Democrats who support “Obamacare.” Defenders of reform emphasized that the mandate delay demonstrates administration willingness to accommodate constituents, and that exchanges and relevant policies are on track.
Exchange challenges
HHS has the huge task of operating a federally facilitated exchange (FFE) for 34 states-with 15 states carrying out some functions like plan management. Only 16 states and D.C. are setting up their own exchanges.
In June, the Government Accountability Office (GAO) issued a warning that many exchange operations may not be fully functional on time. The employer-mandate delay lowered projections, calculating that some 30 million will remain without insurance-not 23 million. Insurers are busy recalculating market potential, risk adjustment strategies, marketing plans and systems for ensuring accurate enrollment and payment data.
Last month, HHS awarded a $1.2 billion, five-year contract to defense contractor Serco to process and review individual applications filed with exchanges and to determine penalty exemptions and subsidy qualifications. Contractors have also signed on to run call centers and the federal “data hub.” Final rules were issued for training navigators as well.
Before consumers can obtain comparative information on insurance options, exchange operators have to assess plans for actuarial value, essential benefits, network adequacy and nondiscriminatory features.
Most states have adopted a clearinghouse model that allows all qualified carriers to market plans via the exchange. While the federal government won’t be an “active purchaser” that blocks high-cost plans from exchange listing, the HHS secretary recently said that the government must take a close look at premiums and indicate to insurers if they are comparatively expensive.
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More